We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma (LEE001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02524119
Recruitment Status : Terminated (This study was terminated after the sponsor withdrew our support)
First Posted : August 14, 2015
Results First Posted : February 1, 2021
Last Update Posted : February 1, 2021
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Muhammad Beg, University of Texas Southwestern Medical Center

Brief Summary:
The purpose of this study is determine whether the combination therapy with LEE011 and chemoembolization in patients with locally advanced Hepatocellular Carcinoma not amenable to curative therapies will provide greater efficacy than chemoembolization alone with a tolerable safety profile.

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Drug: LEE011 Procedure: Chemoembolization Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib/II Study of LEE011 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma
Actual Study Start Date : April 2016
Actual Primary Completion Date : September 2020
Actual Study Completion Date : September 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Ribociclib

Arm Intervention/treatment
Experimental: LEE001 with Chemoembolization
A total of 40 patients will be enrolled and undergo chemoembolization. Patients will receive LEE011 (600 mg PO once daily, 3 weeks on/1 week off) on Day 1 with chemoembolization. Patients can receive a total of 4 chemoembolization treatments within 6 month following first treatment as needed to treat initial HCC lesion.
Drug: LEE011
600 mg PO once daily will be given orally on days 1-21 of a 28 day cycle (3 weeks on / 1 week off) :until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason

Procedure: Chemoembolization
Patients will be treated with chemoembolization once every 4 weeks with up to 4 total chemoembolizations within the first 6 months from the initial chemoembolization.

Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: Every 8 weeks for up to 3 years. ]
    CT Chest scans must be performed at baseline. CT-Chest/abdomen/pelvis must be performed every 8 weeks during the treatment phase (12 months). Once the patient has been discontinued from the study and enters the efficacy phase, radiological assessment (CT or MRI) will continue every 8 weeks until progression or for the first 12 months, whichever comes first. After a year, radiological (CT or MRI) assessments will be performed every 12 weeks for up to 1 year.

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: Every 12 weeks for up to 3 years. ]
    CT Chest scans must be performed at baseline. CT-Chest/abdomen/pelvis must be performed every 8 weeks during the treatment phase (12 months). Once the patient has been discontinued from the study and enters the efficacy phase, radiological assessment (CT or MRI) will continue every 8 weeks until progression or for 3 years, whichever comes first. After a year, radiological (CT or MRI) assessments will be performed every 12 weeks for up to 3year.

  2. Number of Participants With Adverse Events [ Time Frame: Each visit for up to 3 years ]
    Adverse events will be determined according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.

  3. Tolerability, as Measured by Number of Adverse Events [ Time Frame: At each patient visit while on LEE001 for up to 3 years ]
    The tolerability of LEE in combination with chemoembolization will be measured by number of adverse events.

  4. Objective Response Rate (ORR) Based on mRECIST and RECIST 1.1 [ Time Frame: Every 8 weeks for 3 years ]
    ORR was defined as number of participants with confirmed complete response (CR) or confirmed partial response (PR) according to the RECIST 1.1.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient must have a histologically confirmed diagnosis of RB positive hepatocellular carcinoma
  2. Patients must have HCC limited to the liver. There must be no clinical or radiographic evidence of extrahepatic HCC. Portal lymphadenopathy is permitted as lymphadenopathy is commonly associated with cirrhosis unrelated to malignancy;
  3. Absence of occlusive main portal vein thrombus, branch venous thrombus is allowed;
  4. Patients with locally advanced HCC not eligible for curative therapies;
  5. Age ≥ 18 years;
  6. Child-Pugh Score A or B7;
  7. ECOG (Eastern Cooperative Oncology Group) Performance score of 0-2;
  8. Life expectancy greater than 6 months;
  9. Following baseline laboratory values:
  10. Total bilirubin ≤ 3.0 x ULN or direct bilirubin ≤1.5 x ULN in patients with well-documented Gilbert's Syndrome;
  11. INR (international normalized ratio) ≤ 1.7;
  12. Hgb ≥ 9.0 g/dl;
  13. Alkaline Phosphatase, AST (Aspartate Aminotransferase), ALT (Alanine Aminotransferase) <7 times ULN;
  14. Platelet count ≥ 75,000/mm3;
  15. Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 50 mL/min;
  16. Absolute neutrophil ≥ 1,500 cells/mm3;
  17. Potassium, total calcium (corrected for serum albumin), magnesium, and phosphorus within normal limits for the institution or corrected to within normal limits with supplements before first dose of study medication
  18. Sodium >130 meq/L;
  19. Women of childbearing potential must have a negative pregnancy test;
  20. Prior therapy is allowed provided the following are met: at least 4 weeks since prior locoregional therapy including surgical resection, chemoembolization, radiotherapy, or ablation. Provided target lesion has increased in size by 25% or more or the target lesion was not treated with locoregional therapy;
  21. Must be able to swallow LEE011 capsules.

Exclusion Criteria:

  1. Patient who received any CDK4/6 inhibitor (cyclin-dependent kinase 4);
  2. Patient who has received previous systemic therapy;
  3. Patients with central nervous system (CNS) involvement, unless they meet ALL of the following criteria:
  4. At least 4 weeks from prior therapy completion (including ration and/or surgery) to starting the study treatment;
  5. Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases;
  6. Clinically significant, uncontrolled heart disease and/or recent events including any of the following:
  7. History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 12 months prior to screening;
  8. History of documented congestive heart failure (New York Heart Association functional classification III-IV);
  9. Documented cardiomyopathy;
  10. Patient has a left ventricular ejection fraction <50% as determined by MUGA (Multi Gated Acquisition scan) or ECHO at screening;
  11. History of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrythmias, or conduction abnormality within 12 months of screening;
  12. Bradycardia (heart rate <50 at rest), by ECG or pulse, at screening;
  13. Congenital long QT syndrome or family history of long QT syndrome;
  14. Systolic Blood Pressure (SBP) >160 or <90 mm Hg;
  15. On screening inability to determine the QTcF (Fridericia Correction Formula) interval on the ECG (i.e.: Unreadable or Not Interpretable) or QTcF > 450 msec (using Fridericia's correction). All as determined by screening ECG (mean of triplicate ECGs);
  16. Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to treatment (see appendix 1 for details):
  17. Known strong inducers or inhibitors of CYP3A4/5 (a member of the cytochrome P450), including grapefruit, grapefruit hybrids, pomelo, star-fruit, and Seville oranges;
  18. That have a known risk to prolong the QT interval or induce Torsades de Pointes
  19. Herbal preparations/medications, dietary supplements;
  20. That have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5;
  21. Tumor involvement > 50% of the liver;
  22. Patient has a known history of HIV infection (testing is not required);
  23. Patient has any other concurrent sever and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial, or viral infections, etc.);
  24. Patient is currently receiving or has received systemic corticosteroids ≤ 2 weeks to starting study drug, or who have not fully recovered from side effects of such treatment
  25. The following uses of corticosteroids are permitted: single doses, topical applications (e.g.: for rash), inhaled sprays (e.g.: for obstructive airways diseases), eye drops or local injections (e.g.: intra-articular);
  26. Patient is currently receiving warfarin or other Coumadin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed;
  27. Participation in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer;
  28. Patient who has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom ≥ 30-25% of the bone marrow was irradiated;
  29. Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery);
  30. Patient has not recovered from all toxicities related to prior anticancer therapies to NCI-CTCAE version 4.03 Grade <1 (Exception to this criterion: patients with any grade of alopecia are allowed to enter the study);
  31. Patient has a known hypersensitivity to any of the excipients of LEE011;
  32. Prior ablative, radiation, resection, or transplant therapies less than 4 weeks before study registration;
  33. Active gastrointestinal bleeding;
  34. Allergy to iodine or gadolinium contrast that cannot be safely controlled with premedication;
  35. Concurrent malignancy or malignancy within 3 years of study entry, with the exception of adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer or treated cervical cancer;
  36. Contraindication to angiography or chemoembolization medications;
  37. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after contraception and until the termination of gestation, confirmed by a positive hCG (Human chorionic gonadotropin) laboratory test;
  38. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study and for 8 weeks after study drug discontinuation. Highly effected contraception methods include:
  39. Total abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
  40. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
  41. Male sterilization (at least 6 months prior to screening). For female patients on the study, the vasectomized male partner should be the sole partner for that patient.
  42. Combination of any of the two following (a+b or a+c or b+c) 43A-Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception; 45 B-Placement of an intrauterine device (IUD) or intrauterine system (IUS); 45 C-Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository in case of use of oral contraception, women should have been stable on the same pill before taking study treatment.

Note: Oral contraceptives are allowed but should be used in conjunction with a barrier method of contraception due to unknown effect of drug-drug interaction. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

46-Sexually active males, unless they use a condom during intercourse while taking the drug, and for 21 days after stopping treatment of LEE011 -- should not father a child in this period. A condom is required to be used also by vasectomized male in order to prevent delivery of the drug via seminal fluid.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02524119

Layout table for location information
United States, Texas
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Novartis Pharmaceuticals
Layout table for investigator information
Principal Investigator: Muhammad Beg, MD University of Texas Southwestern Medical Center
  Study Documents (Full-Text)

Documents provided by Muhammad Beg, University of Texas Southwestern Medical Center:
Layout table for additonal information
Responsible Party: Muhammad Beg, Associate Professor of Medicine, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT02524119    
Other Study ID Numbers: STU 052015-073
First Posted: August 14, 2015    Key Record Dates
Results First Posted: February 1, 2021
Last Update Posted: February 1, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases